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Abstract
Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor 
gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, 
hemangioblastoma, and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in 
hypoxia inducible factor (HIF)-α regulation. Murine embryonic stem (ES) cells in which the 
endogenous wild-type Vhl gene was replaced with the representative Type 2B VHL hotspot 
mutation R167Q (Vhl2B/2B) displayed preserved physiologic regulation of both HIF factors with 
slightly more normoxic dysregulation of HIF-2α. Differentiated Vhl2B/2B-derived teratomas over-
expressed the joint HIF targets Vegf and EglN3 but not the HIF-1α-specific target Pfk1 and 
displayed a growth advantage over Vhl-/--derived teratomas, suggestive of a tight connection 
between perturbations in the degree and ratio of HIF-1α and HIF-2α stabilization and cell growth. 
Vhl2B/2B mice displayed mid-gestational embryonic lethality, while adult Vhl2B/+ mice exhibited 
susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at 
twelve months. Our experiments support a model in which the representative Type 2B R167Q 
mutant pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-specific 
effects on cell growth, development, and tumor predisposition.
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
*Corresponding author: W. Kimryn Rathmell, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel 
Hill, 450 West Drive, Room 21-237, Campus Box 7295, Chapel Hill, NC 27599-7295, Telephone: (919) 966-3522, Fax: (919) 
966-8212, E-mail: rathmell@med.unc.edu. 
HHS Public Access
Author manuscript
Oncogene. Author manuscript; available in PMC 2009 October 09.
Published in final edited form as:














von Hippel-Lindau; hypoxia inducible factors; renal cell carcinoma
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer susceptibility 
syndrome resulting from germline mutation of the VHL tumor suppressor gene which affects 
1 in 36,000 live births in the US (Maher et al., 1991; Neumann & Wiestler, 1991). Specific 
classes of VHL mutations predispose to different spectrums of morbidity- and mortality-
causing clinical phenotypes of VHL disease: retinal and central nervous system (CNS) 
hemangioblastoma, pheochromocytoma/paraganglioma, and renal cell carcinoma with clear 
cell histology (ccRCC) (Crossey et al., 1994; Zbar et al., 1996). Type 1 VHL mutations 
predispose to ccRCC and hemangioblastoma (Gallou et al., 2004). Type 2 missense VHL 
mutations predispose to pheochromocytoma, either alone (Type 2C) or in combination with 
hemangioblastoma and a high (Type 2B) or low (Type 2A) risk of ccRCC (Clifford et al., 
2001). Finally, individuals with homozygosity for the germline R200W VHL mutation 
develop Chuvash Polycythemia (CP), a rare benign congenital erythrocytosis with no 
associated cancer risk (Ang et al., 2002; Pastore et al., 2003).
The VHL gene encodes a 30 kDa protein, pVHL (Iliopoulos et al., 1995; Latif et al., 1993). 
Wild-type pVHL has been reported to play roles in diverse biological processes including 
acting as the recognition domain for an E3 ubiquitin ligase complex (Iwai et al., 1999; 
Lisztwan et al., 1999) composed of Elongins B and C (Duan et al., 1995; Kibel et al., 1995), 
cullin-2 (Pause et al., 1997), ROC1 (Rbx1) (Kamura et al., 1999), and an E2 conjugating 
enzyme (Iwai et al., 1999; Kamura et al., 2000). pVHL E3 ligase activity targets hypoxia 
inducible factor (HIF)-α subunits (Cockman et al., 2000; Iliopoulos et al., 1996; Maxwell et 
al., 1999; Ohh et al., 2000), a family of transcription factor subunits including HIF-1α and 
HIF-2α.
HIF-1α and HIF-2α coordinate cellular and whole-organism responses to hypoxia and are 
controlled at the level of stability and activity by oxygen-dependent hydroxylation. In 
normoxic conditions, a family of prolyl hydroxylases (Bruick & McKnight, 2001; Epstein et 
al., 2001; Ivan et al., 2002; Ivan et al., 2001) mediates the hydroxylation of HIF-α prolyl 
residues (Huang et al., 2002; Huang et al., 1998; Jaakkola et al., 2001; Pugh et al., 1997), 
targeting HIF-α to pVHL for degradation (Hon et al., 2002; Min et al., 2002). In hypoxic 
conditions, the prolyl hydroxylases are inactive (Epstein et al., 2001; Jiang et al., 1997; Pugh 
et al., 1997), resulting in stabilized, transcriptionally active HIF-α. Stabilized HIF-α 
heterodimerizes with ARNT/HIF-1β (Jiang et al., 1996) to activate the transcription of target 
genes (Semenza et al., 1996; Tian et al., 1997). HIF-1α and HIF-2α target gene sets overlap 
in a highly context-dependent manner (Semenza, 2003), but HIF-1α uniquely activates 
glycolytic enzymes (Hu et al., 2003).
Several lines of evidence implicate the VHL/HIF axis in the initiation of renal 
tumorigenesis. First, biallelic inactivation of VHL and over-expression of HIF targets is 
observed in both VHL disease-associated renal lesions and also 70-90% of sporadic ccRCC 
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tumors (Banks et al., 2006; Foster et al., 1994; Kondo et al., 2002; Nickerson et al., 2008). 
Second, over-expression of HIF targets accounts for many histological and clinical features 
of ccRCC tumors, including their highly vascular natures and paraneoplastic erythrocytosis 
(Rathmell & Chen, 2008). Third, Vhl loss in primary cells directly results in upregulation of 
both HIF-1α and HIF-2α and recapitulates many features of RCC (Mack et al., 2003). 
Finally, emerging evidence points to the degree of HIF dysregulation impacting renal 
tumorigenesis. In vitro studies of cDNA expressed Type 2A and Type 2B mutant pVHL 
models revealed graded dysregulation of HIF-1α and HIF-2α (Clifford et al., 2001; 
Cockman et al., 2000), correlating with the degree of risk for ccRCC (Type 1≥ Type 2B > 
Type 2A) (Knauth et al., 2006; Li et al., 2007). Additionally, while Type 2B mutations are 
predicted to disrupt pVHL:Elongin C interactions, preservation of HIF ubiquitylation 
activity has been observed, which would provide a permissive environment for HIF 
regulation (Hacker et al, 2008). The profile of HIF dysregulation may also have 
ramifications for tumor predisposition, as selective HIF-2α stabilization has been observed 
in murine embryonic stem (ES) cells transgenic for a Type 2B mutant VHL gene (Rathmell 
et al., 2004). These systems in addition to demonstrating mutation specificity are sensitive to 
pVHL levels.
Existing mouse models of VHL disease utilize null (Gnarra et al., 1997) or conditional null 
(Haase et al., 2001; Ma et al., 2003) Vhl alleles, display homozygous embryonic lethality, 
and show a high penetrance of hepatic angiomas, uncommon in the human disease. A Vhl 
gene replacement model of Chuvash Polycythemia, however, was viable and conferred 
erythrocytosis in a milieu of very mild HIF-2α stabilization (Hickey et al., 2007). To 
examine the activities of mutant pVHL relevant to human cancer, particularly with respect 
to missense mutation-specific effects on HIF regulation, we undertook a gene replacement 
approach to study Type 2B VHL disease in a mouse model. This model provides the first 
opportunity to examine the effect of a VHL disease-causing missense mutations in its pre-
malignant context and under endogenous transcriptional, translational, and post-translational 
regulation. Murine ES cells homozygous for a representative mutant 2B Vhl allele displayed 
mild HIF-2α stabilization but functionally preserved HIF-1α suppression. In vivo, while 
homozygosity for the mutant 2B Vhl allele conferred mid-gestational embryonic lethality, 
heterozygous Vhl2B/+ mice were viable and susceptible to carcinogen-promoted renal 
adenocarcinoma. Our genetic knock-in mouse model thus provides a species-congruent 
cellular system and in vivo model in which to further examine the contributions of Type 2B 
VHL missense mutation to VHL disease-associated cancers.
Results
Generation and characterization of Type 2B Vhl ES cell lines
The Arginine 167 → Glutamine (R167Q) missense mutation is a hotspot in the human VHL 
gene with a tight genotype-phenotype correlation to Type 2B disease (Maher et al., 1991; 
Zbar et al., 1996). Localized to the pVHL α helical domain (Figure 1A), R167 is predicted 
to stabilize the α/β domain interface and interaction with Elongin C (Ohh et al., 1999; 
Stebbins et al., 1999). In the murine Vhl allele, this mutation corresponds to a guanine to 
alanine transition at position 518 (G518A).
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To study the effect of 2B mutant pVhl on regulation of HIF-α and HIF targets, we targeted 
the endogenous murine Vhl locus with an R167Q mutant Vhl construct (Figure 1B) to 
generate Vhl2B/+ and Vhl2B/2B ES cell lines. The targeting construct introduced a HindIII 
site, enabling verification of recombination by Southern analysis (Figure 1C), and the 
G518A mutation introduced a novel HpyIV restriction site for restriction-based PCR 
genotyping (Figure 1D). Quantitative RT-PCR analysis in Vhl2B/2B ES cells confirmed that 
2B mutant Vhl was transcribed at wild-type levels (Figure 2A). Vhl2B/+ cells expressed wild-
type levels of pVhl, but Vhl2B/2B cells expressed greatly reduced levels of the 2B mutant 
pVhl (Figure 2B). A similar reduction in detectable 2B mutant pVhl was also observed by 
immunoblot with an antibody raised against an alternate epitope suggesting that reduced 
detection of 2B mutant pVhl was not due to epitope-masking alone. Rescue with MG-132 
treatment was not observed, consistent with the reduced protein expression and incomplete 
MG-132 rescue observed in the Chuvash Polycythemia Vhl gene replacement model 
(Hickey et al., 2007).
Analysis of HIF and HIF target expression in Type 2B Vhl ES cells
The R167Q human pVHL mutation is predicted to destabilize the pVhl protein (Knauth et 
al., 2006) and to disrupt pVhl recruitment of Elongin C (Stebbins et al., 1999), resulting in 
HIF factor dysregulation. ES cells in the presence or absence of the chemical hypoxia 
mimetic cobalt chloride (CoCl2) were examined for HIF-1α (Figure 2C) and HIF-2α (Figure 
2D) protein levels by immunoblot. Wild-type and Vhl2B/+ ES cells displayed low basal 
levels of HIF-1α and HIF-2α and responded to CoCl2 exposure with induction of both 
factors. Vhl-/- ES cells displayed maximal stabilization of both HIF-1α and HIF-2α without 
further induction. In contrast, Vhl2B/2B ES cells retained physiologic induction of both HIF-α 
factors with CoCl2. While normoxic HIF-1α levels in Vhl2B/2B cells were similar to wild-
type cells in independently-derived clones (Figure 2C), normoxic HIF-2α levels tended to be 
modestly elevated (Figure 2D). Qualitative comparisons were confirmed by densitometry 
analysis (Supplemental Figure 1).
HIF-2α is transcriptionally inactive in ES cells (Hu et al., 2006). To determine whether 
Vhl2B/2B ES cells activate transcription of HIF target genes, we performed quantitative (q) 
RT-PCR for four known HIF target mRNAs (Figure 2E): the joint HIF-1α and HIF-2α 
targets vascular endothelial growth factor (Vegf), glucose transporter 1 (Glut1), and prolyl 
hydroxylase three (EglN3) and the HIF-1α-specific glycolytic enzyme phosphofructokinase 
(Pfk1). Vhl-/- ES cells displayed transcription of all four HIF target mRNAs relative to wild-
type J1 cells (p<0.05): Vegf (4.26-fold), Glut1 (2.66-fold), EglN3 (11.80-fold), and Pfk1 
(2.32-fold). Two independently-derived Vhl2B/2B clones, in contrast, failed to significantly 
over-transcribe any of the four HIF targets, consistent with the observation that Vhl2B/2B ES 
cells exhibit wild-type HIF-1α expression. Mirroring the qRT-PCR results, Vhl-/- ES cells 
secreted robust levels of Vegf protein (4.4-fold) compared to wild-type (p<0.01), while 
Vhl2B/2B ES cells did not secrete measurable Vegf (Figure 2F).
Type 2B Vhl promotes teratoma growth and vascularization
To observe the functional effects of Type 2B Vhl mutation, we differentiated our panel of 
ES cells in a teratoma assay. As expected from previous studies (Rathmell et al., 2004), 
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Vhl-/--derived teratomas displayed a growth disadvantage. In contrast, the presence of one or 
two Type 2B Vhl alleles conferred a persistent growth advantage, such that Vhl2B/2B-derived 
teratomas grew faster than Vhl2B/+-derived teratomas, which in turn grew faster than wild-
type teratomas (Figure 3A). At harvest, J1, Vhl-/-, and Vhl2B/+ teratomas were well-
encapsulated, while Vhl2B/2B teratomas adhered to the overlying skin (not shown). Vhl2B/2B 
teratomas (Figure 3B, left) were also grossly hemorrhagic compared to Vhl2B/+ (Figure 3B, 
right) teratomas. Histologically, Vhl-/- teratomas were characterized by hemangioma (*) 
formation (Figure 3E), which was markedly enhanced in Vhl2B/2B teratomas (Figure 3F).
To determine whether Type 2B mutant pVhl preserves HIF regulation in vivo, teratomas 
were analyzed for HIF-1α and HIF-2α protein expression by immunoblot, confirming low 
levels of both HIF factors (Supplemental Figure 2). To evaluate the effect on target gene 
expression, we performed quantitative RT-PCR for the panel of HIF target genes described 
above in three independent sets of teratomas. In one representative set (Figure 3G), the Vhl-/- 
teratoma displayed highly significant (p<0.001) over-expression of three of the four HIF 
targets relative to the J1 teratoma: Vegf (1.99-fold), EglN3 (3.15-fold), and Pfk1 (2.12-fold). 
In contrast to ES cells, the Vhl2B/2B-derived teratoma exhibited significant over-expression 
of both EglN3 (1.46-fold, p<0.05) and Vegf (1.87-fold, p<0.001) but failed to over-express 
the HIF-1α-specific target Pfk1. Glut1 expression was not elevated for either Vhl mutant in 
this differentiated system.
To explore the differences in vascular proclivities between Vhl-/- and Vhl2B/2B teratomas, we 
performed a screen for candidate angiogenesis-related genes (Supplemental Table 1 and 
Figure 4). Four novel angiogenesis-related candidate genes, in addition to Vegfa, were 
uncovered in the candidate screen and validated by qRT-PCR with independent primers : 
vascular endothelial (VE)-cadherin (Cdh5), the TgfβR endothelial co-receptor endoglin 
(Eng), Vegf receptor 2 (Kdr), and the Vegfr2 co-receptor neuropilin-1 (Nrp1). All four are 
considered direct HIF targets (Brusselmans et al., 2005; Elvert et al., 2003; Le Bras et al., 
2007; Sanchez-Elsner et al., 2002). While both the Vhl-/- and Vhl2B/2B teratomas 
significantly over-expressed Cdh5, Eng, and Kdr relative to the J1 teratoma, the Vhl2B/2B 
teratoma additionally significantly (p<0.001) over-expressed Nrp1 relative to both J1 and 
Vhl-/- (Figure 4).
Homozygosity for Type 2B Vhl confers embryonic lethality
To examine 2B mutant pVhl function in murine development in vivo, we derived Vhl2B/+ 
knock-in mice from our targeted murine ES cells. Inter-heterozygous matings resulted in a 
2:1 ratio of Vhl2B/+ to wild-type pups and a complete absence of Vhl2B/2B pups (Table 1). To 
pinpoint the window of Vhl2B/2B intrauterine demise, we genotyped embryos resulting from 
timed matings at embryonic day (E) 9.5 and E10.5. While Vhl2B/2B embryos were present at 
near-expected levels at E9.5, only one Vhl2B/2B embryo (3%) survived at E10.5. Because 
reliance switches from yolk sac to placenta around E9.5 (Alvarez-Silva et al., 2003), 
Vhl2B/2B embryonic lethality observed at E9.5-E10.5 implicates placental failure.
Vhl-/- embryos display embryonic lethality at E9.5-E12.5 due to an embryonic-origin defect 
in placental labyrinth vascularization. While the presumptive Vhl-/- labyrinth is normal in 
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histological appearance at E9.5, Vhl-/- allantoic vessels fail to invade the chorionic plate, 
preventing induction of chorionic plate trophoblast cell differentiation into 
syncitiotrophoblast cells and later manifesting as an absence of fetal blood spaces in the 
labyrinth at E10.5 (Gnarra et al., 1997). To visualize whether the 2B mutant Vhl allele acts 
similarly to the null allele in the placenta, we compared wild-type (not shown), Vhl2B/+, and 
Vhl2B/2B placentas by H&E for morphology and IHC for pVhl and the HIF target Vegfa. By 
H&E, representative E9.5 Vhl2B/+ (Figure 5A) and Vhl2B/2B (Figure 5D) placentas displayed 
comparable chorionic villous fold formation and maternal red blood cell content in the 
spongiotrophoblast layer, but allantoic vessels, demarcated by the presence of nucleated 
fetal red blood cells (*), invaded the chorionic villi to a lesser extent in the Vhl2B/2B 
placenta. Despite the reduced Type 2B pVhl levels observed by immunoblot in Vhl2B/2B ES 
cells, spongiotrophoblast and giant cell pVhl expression was comparable between 
representative Vhl2B/2B (Figure 5E) and Vhl2B/+ (Figure 5B) placentas by IHC. Finally, 
consistent with findings in Vhl-/- placentas at E10.5 (Gnarra et al., 1997), Vhl2B/2B placenta 
(Figure 5F) displayed absent or greatly reduced spongiotrophoblast and giant cell Vegf 
expression relative to Vhl2B/+ (Figure 5C) by IHC. While perhaps counter-intuitive, evidence 
supports decreased Vegf expression as a marker of placental failure rather than an indicator 
of HIF dysregulation in the murine placenta (Voss et al., 2000).
Because E9.5 embryos were the only Vhl2B/2B animal tissues available for molecular study, 
we used these tissues to analyze the competence of Type 2B pVhl to regulate HIF target 
genes in vivo. Though Vhl2B/2B embryos are grossly and histologically normal at E9.5, we 
hypothesized that they might still demonstrate subtle HIF target gene dysregulation. 
Quantitative RT-PCR on three Vhl2B/2B E9.5 embryos showed significant (p<0.05) over-
expression of the four HIF target genes studied relative to a Vhl2B/+ E9.5 embryo, paralleling 
the effect of Vhl mutation on HIF-regulated signaling observed in the differentiated teratoma 
model system (Figure 5G): Vegf (average 1.54-fold), Glut1 (average 2.60-fold), EglN3 
(average 3.53-fold), and Pfk1 (average 1.88-fold). In notable contrast to ES cells and 
teratomas and in keeping with the reported highly tissue- and context-specific transcriptional 
effects of HIF stabilization, homozygosity for the 2B Vhl allele produced sufficient HIF-1α 
dysregulation to permit over-expression of the HIF-1α-specific target Pfk1 in the E9.5 
embryo, with potential contribution by physiologic embryonic hypoxia.
Heterozygous Type 2B Vhl mice develop renal cysts
As Type 2B VHL disease predisposes to pheochromocytoma, hemangioblastoma, and 
ccRCC in humans, Vhl2B/+ mice (n=105) were aged to three, six, nine, twelve, and eighteen 
months and observed for tumor susceptibility. Representative H&E images of Vhl2B/+ 
tissues at twelve months are presented in Figure 6 (A-C). Similar to prior models, Vhl2B/+ 
mice displayed frequent enlarged vessels (angiectasis) in the kidney and adrenal gland 
(Figure 6B, *) (Gnarra et al., 1997; Haase et al., 2001; Ma et al., 2003) and renal cortical 
microcysts (3%, Figure 6A, Cy) (Haase et al., 2001). Renal cortical cysts were not observed 
in wild-type littermates. In contrast to prior studies, Vhl2B/+ liver histology was uniformly 
normal (Figure 6C).
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Transplacental mutagenesis promotes renal tumorigenesis in Type 2B Vhl mice
We hypothesized that accelerating somatic mutations via mutagenesis might reveal 
predisposition to cancer development in Vhl2B/+ mice. Transplacental N-ethyl-N-nitrosourea 
(ENU) mutagenesis has been used successfully to augment renal cystogenesis in mouse 
models of Tuberous Sclerosis (Kobayashi et al., 1999), another renal tumor predisposition 
syndrome, and therefore was an ideal method for accelerating progression in our model. 
Wild-type and Vhl2B/+ embryos from timed inter-heterozygous matings were treated with 
ENU at E14.5 and allowed to age to four (n=12) and twelve months (n=24) in a pilot study. 
At sacrifice, grossly abnormal organs and organs of interest were harvested. Renal lesions 
observed in mutagenized mice are summarized in Table 2.
At four months, both wild-type (2/4) and Vhl2B/+ (6/8) mutagenized mice displayed 
macroscopic subpleural lung nodules, indicating successful ENU mutagenesis (Miller, 
2004). Both wild-type and Vhl2B/+ mutagenized mice displayed simple and papillary cortical 
renal microcysts on H&E-stained sections, suggesting that ENU mutagenesis effectively 
promotes benign renal cyst formation in this C57BL/6 genetic background. While all three 
papillary renal cysts observed in mutagenized wild-type mice displayed benign histology, 
the papillary cyst in observed in a mutagenized Vhl2B/+ mouse displayed pre-neoplastic 
changes (not shown).
At twelve months, histological findings in wild-type mutagenized mice were limited to 
benign papillary cysts (Figure 6D). However, Vhl2B/+ mutagenized mice (2/10) developed 
pathological findings typical of VHL disease. One Vhl2B/+ mouse developed a borderline 
clear-cell adenoma/adenocarcinoma (Figure 6E) featuring a large nest of cells (alveolus) 
with clear-cell histology, vascular stroma, and absent tubular architecture as well as several 
clear-cell alveoli invading into the underlying renal cortex. A second affected Vhl2B/+ mouse 
developed adenocarcinoma (Figure 6F) featuring nests of clear cells, central necrosis, absent 
tubular architecture, vascular stroma, and a poorly defined border. Statistical analysis 
suggested that Vhl mutation correlated with or trended toward development of neoplasia at 
12 months (Pearson’s χ2 p=0.037, Fisher’s exact test p=0.101).
Discussion
Germline Type 2B missense mutations in VHL predispose to ccRCC, CNS and retinal 
hemangioblastoma, and pheochromocytoma and paraganglioma. In our murine gene 
replacement system, which models one VHL type 2B disease mutation, R167Q, generated a 
unique pattern of HIF-1α and HIF-2α dysregulation, differing from Vhl-null both in degree 
and ratio of HIF stabilization as well as in functional outcome in in vitro and in vivo studies.
Our gene replacement system takes advantage of the euploid genetic background of murine 
ES cells and avoids the potential mouse-human interactions and over- and mis-expression 
artifacts inherent to transgenic models. We observed reduced levels of 2B mutant pVhl 
protein in homozygous ES cells, supporting the hypothesis that ccRCC-predisposing VHL 
missense mutations produce less stable proteins, as posited on the basis of structure analysis 
(Knauth et al., 2006; Stebbins et al., 1999). In contrast to Vhl-/- ES cells, Vhl2B/2B knock-in 
ES cells expressed low basal levels of HIF-1α and HIF-2α and induced both subunits 
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physiologically in response to the hypoxia mimetic CoCl2. Consistent with this finding, 
Vhl2B/2B ES cells displayed wild-type levels of four HIF target genes studied, suggesting 
that HIF-1α levels in Vhl2B/2B cells failed to surpass a threshold required for transcriptional 
activation at target promoters in this cell type.
The differentiated teratoma system allowed observation of 2B mutant pVhl function in a 
setting permissive for both HIF-1α and HIF-2α transcriptional activity. Previous work in 
Vhl-/- teratomas has demonstrated that maximal activation of both HIF-1α and HIF-2α 
promotes angiogenesis but retards three-dimensional tumor growth (Mack et al., 2003). 
Genetic knock-out of HIF-1α (Carmeliet et al., 1998) or replacement of HIF-1α with 
HIF-2α (Covello et al., 2005) in teratomas enhances tumor growth and implicates HIF-1α as 
the growth-suppressive factor in this assay. In our studies, Vhl-/- teratomas likewise 
displayed a growth disadvantage relative to wild-type and additionally featured over-
expression of the joint HIF targets Vegfa and EglN3 and the HIF-1α-specific target Pfk1, all 
indicating HIF-1α and HIF-2α stabilization. Vhl2B/2B teratomas, in contrast, displayed a 
marked growth advantage relative to wild-type, and over-expression of Vegfa and EglN3, 
but not Pfk1, suggestive of sub-threshold HIF-1α but sufficient HIF-2α stabilization to 
promote transcriptional activity.
The placental failure and lethality observed in Vhl2B/2B embryos at E9.5-E10.5 was 
consistent with severely hypomorphic mutant pVhl function in the embryonic allantoic 
endothelium. Reduced pVhl stability alone is unlikely to be the cause of Vhl2B/2B embryonic 
lethality. First, 2B mutant pVhl levels in the E9.5 Vhl2B/2B placenta were similar to pVhl 
levels observed in the E9.5 Vhl2B/+ placenta by IHC. Second, VhlCP/CP mice are viable 
despite the measurable instability of R200W (CP) pVhl both in vitro and in murine tissues 
(Hickey et al., 2007). Finally, there is evidence of more severe HIF dysregulation in this in 
vivo system, with evidence of induction of the HIF-1α-specific target Pfk1, indicating both 
HIF-1α and HIF-2α stabilization. Thus, while it remains possible that the degree of pVhl 
reduction has a threshold effect on early developmental events, the reduced levels in these 
models serves to unmask added levels of regulation of the HIF transcriptional network.
Vhl2B/+ mice developed renal cysts with frequency similar to that observed in Vhl+/- mice 
(∼3%) and likewise failed to develop dysplasia or renal adenocarcinoma, indicating that Vhl 
mutation alone is insufficient for invasive renal tumor formation in the murine kidney To 
accelerate the accumulation of somatic mutations in this mouse model and reveal tumor 
predisposition, we mutagenized Vhl-initiated and wild-type littermate mice with 
transplacental ENU. At twelve months post-ENU, renal adenocarcinoma was observed in 
mutagenized Vhl2B/+ mice, representing the first demonstration of this tumor in a 
genetically-predisposed mouse model and validating Vhl mutation as a tumor-initiating 
event in the development of RCC.
Our gene replacement model of the representative Type 2B R167Q Vhl mutation bolsters 
emerging evidence that relative HIF-1α and HIF-2α protein abundance modulates the VHL 
Disease clinical phenotype and provides motivation for identifying the relevant genetic 
events involved in progressing Vhl-initiated tumors to invasive disease. More broadly, our 
Vhl gene replacement model provides a comprehensive species-congruent system for future 
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investigations of mutant pVhl HIF and non-HIF functions underpinning human VHL 
Disease both in vitro and in vivo.
Materials and Methods
Generation of Vhl Type 2B ES cell lines and heterozygous mice
Vhl exons 2 and 3 (E2 and E3) were cloned into targeting and mutagenesis vectors, 
respectively, from a BAC clone as previously described (Covello et al., 2005; Hickey et al., 
2007). PCR-based site-directed mutagenesis of G→A at position 518 was performed using 
forward primer 5′-AGAGCCTGGTCAAGCCTGAGAACTA-3′ and reverse primer 5′-
GCACAACCTGAAGGCACCGCTCTTT-3′. The G518A mutant E3 fragment was then 
cloned into pLNT-E2 adjacent to the neoR cassette (pLNT-E2-E3) and reconfirmed with 
bidirectional sequencing.
The pLNT-E2-E3 targeting construct (Figure 1B) was electroporated into Vhl wild-type J1 
strain Sv/129 ES cells for gene replacement at the endogenous murine Vhl locus. 
Homologous recombinants heterozygous for the Vhl2B neo-in allele were selected by 
gancyclovir and neomycin resistance, and positive clones confirmed by Southern blot 
analysis. Conversion of the second Vhl allele was achieved by selection with increasing 
amounts of neomycin to yield ES cells homozygous for the Vhl2B neo-in allele. Vhl2B neo-in/+ 
and Vhl2B neo-in/2B neo-in ES cells were transiently transfected with a cre-expressing vector to 
remove the floxed neoR cassette. The ES cells were screened at each stage by Southern blot 
for in vitro and in vivo studies of Type 2B mutant pVhl function.
Animal Models Core (University of Pennsylvania) staff injected karyotyped Vhl2B neo-in/+ 
ES cells into C57BL/6 blastocysts. The chimeric blastocysts were then implanted in 
pseudopregnant C57BL/6 females. Highly chimeric mice (F0) were selected by Agouti coat 
color for crossing to C57BL/6 females. Germline transmission of the targeted allele to 
Agouti offspring (F1) was confirmed by Southern blot. A Vhl2B neo-in/+ line was crossed to a 
cre deleter mouse strain (EIIa-cre) (Williams-Simons & Westphal, 1999) for multiple 
generations, with excision of the floxed neoR cassette verified by Southern blot, and then 
backcrossed to C57BL/6 to make a Vhl2B/+ founder line. All subsequent generations were 
genotyped by restriction PCR utilizing PCR primers flanking a novel HpyIV restriction site 
introduced by the G518A Vhl mutation (Figure 1D).
All mouse procedures were approved by the University of Pennsylvania and University of 
North Carolina Institutional Animal Care and Use Committees.
Cell Culture Studies
Cell culture studies were performed at 37°C, 5% CO2. ES cell lines were maintained in ES 
media consisting of high glucose Dulbecco’s Modified Eagle Medium (Gibco, Carlsbad, 
CA, USA) supplemented with 5% fetal bovine serum, L-glutamine, β-mercaptoethanol, non-
essential amino acids, and leukemia inhibitory factor (LIF), and grown on gelatin-coated 
tissue culture-grade plates (Corning, Corning, NY, USA). For chemical hypoxia mimetic 
experiments, cells were grown in the presence or absence of CoCl2 (100 μM) for four hours. 
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For proteasome inhibition experiments, cells were treated with vehicle (DMSO) or MG-132 
(5 μM, Calbiochem, San Diego, CA, USA) for four hours.
For in vivo teratoma studies, undifferentiated ES cells of each genotype (5 × 106) were 
injected subcutaneously into the flanks of nu/nu mice (Taconic Labs, Hudson, NY, USA) 
and allowed to grow for six weeks with weekly caliper measurements of tumor size. 
Harvested tumors were bisected and either flash-frozen in liquid nitrogen for molecular 
analysis or formalin-fixed and paraffin-embedded for histological analysis.
Molecular analysis of Vhl, HIF, and HIF targets
Whole-cell protein extracts for immunoblot were prepared in NET lysis buffer (20mM Tris, 
100mM NaCl, 1mM EDTA, 1% NP-40) and quantitated by Bradford assay. Immunoblot 
primary antibodies used were: pVhl (M20 and FL181, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), HIF-1α (10006421, Cayman Chemical, Ann Arbor, MI, USA), HIF-2α 
(NB100-122, Novus Biologicals, Littleton, CO, USA), and eEF2 (Cell Signaling 
Technology, Danvers, MA, USA). Murine Vegf ELISA was performed on conditioned 
medium from cultured ES cells (R & D Systems, Minneapolis, MN, USA).
RNA isolation from ES cells, teratomas, and E9.5 embryos was performed using the RNeasy 
Mini system according to manufacturer’s instructions (Qiagen, Germantown, MD, USA) 
and quantified by UV spectroscopy. cDNA was prepared from 0.5μg of RNA using 
Superscript reverse transcription reagents (Stratagene, Cedar Creek, TX, USA). Quantitative 
RT-PCR was performed in triplicate using stock commercial primer-probe sets for Vhl, 
Vegfa, Glut1, EglN3, Pfk1, and 18S ribosomal subunit according to manufacturer’s 
instructions (Applied Biosystems, Foster City, CA, USA). A candidate screen for teratoma 
hemangioma-associated genes was performed in triplicate on the RT2 Profiler Mouse 
Angiogenesis Array using cycle parameters according to manufacturer’s instructions 
(SABiosciences, Frederick, MD, USA). Genes identified for further validation were 
analyzed by quantitative RT-PCR in triplicate using stock commercial primer-probe sets for 
Cdh5, Eng, Kdr, Nrp1, Vegfc, and 18S ribosomal subunit and cycle parameters according to 
manufacturer’s instructions (Applied Biosystems). All quantitative RT-PCR output raw 
cycle thresholds were normalized to the internal 18S ribosomal RNA standard.
Embryonic lethality and transplacental ethyl nitrosourea (ENU) mutagenesis studies
Vhl2B/+ mice were set up for timed inter-heterozygous mating. Embyronic day (E) 0.5 was 
defined as noon on the day the vaginal plug was observed, and embryos and placentas were 
harvested at E9.5 and E10.5. For placental studies, embryos were examined for gross defects 
and genotyped by restriction PCR, and placentas were processed for histological 
examination. For embryonic studies, E9.5 embryos were used for both RNA extraction and 
genotyping by restriction PCR.
For transplacental mutagenesis studies, intraperitoneal (i.p.) injection of 50 mg/kg ENU 
(Sigma, St. Louis, MO, USA) dissolved in ethanol was administered to the pregnant dam at 
E14.5 (Kobayashi et al., 1999). Mutagenized Vhl2B/+ and wild-type littermates were aged in 
four- and twelve-month cohorts and sacrificed for gross and histological examination.
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Histological analysis of murine tissues
Harvested tissues were fixed in 10% buffered formalin. Paraffin-embedded tissues were 
sectioned and stained with hematoxylin and eosin (H&E) or for pVhl (FL181) or Vegfa 
(VG-1, Santa Cruz).
Statistical analysis
A two-tailed Student’s t test was used to make paired comparisons for quantitative RT-PCR 
and Vegf ELISA data. A value of p≤0.05 was used as the threshold for statistical 
significance. Pearson’s χ2 test and Fisher’s exact test were used to compare development of 
neoplasia in wild-type versus Vhl-mutant mutagenized mice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Type 2B Vhl mutation knock-in strategy and genotyping. A. Human:Mouse pVHL protein 
alignment. The R167Q pVHL substitution representing human Type 2B VHL disease is 
embedded in a highly homologous region. B. Type 2B mutant murine Vhl containing the 
G518A (R167Q) representative missense mutation (star) was prepared with site-directed 
mutagenesis and then cloned into the targeting vector as shown. Following electroporation 
of the targeting vector into J1 ES cells, neomycin and gancyclovir resistance was used to 
select clones with homologous recombination at the endogenous murine locus (Neo-in). Cre 
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recombinase exposure in vitro or in vivo resulted in excision of the floxed NeoR cassette 
(Neo-out). C. Southern blot genotyping distinguished between wild-type and targeted Vhl 
alleles based on the introduction of new HindIII restriction sites. HindIII-digested murine 
Vhl was detected with a probe recognizing the Vhl 3′ untranslated region (UTR, bar). D. 
Restriction PCR was used as an alternative genotyping strategy. Primers (arrows) flanking 
the targeted mutation generated a 300-bp PCR product. The novel restriction site introduced 
by the G518A mutation rendered the targeted Vhl-origin PCR product susceptible to HpyIV 
digestion.
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The Type 2B Vhl missense mutation results in a post-transcriptional reduction in mutant 
pVHL levels and slight normoxic HIF dysregulation but normal normoxic suppression of 
HIF target gene transcription in ES cells. A. Quantitative RT-PCR analysis for Vhl cDNA 
levels in ES cells relative to expression of the wild-type allele. Quantitation was normalized 
to an internal 18S ribosomal RNA standard. Error bars indicate standard error of the mean 
(SEM). B.-D. Immunoblots for pVhl (B.), HIF-1α (C.), and HIF-2α (D.) expression in ES 
cells treated with or without the hypoxia mimetic CoCl2 (Co) for four hours. E. Quantitative 
RT-PCR for normoxic transcriptional activation of HIF targets Vegf, Glut1, EglN3, and Pfk1 
in ES cells relative to J1. Cycle thresholds were corrected with 18S ribosomal RNA. Error 
bars indicate SEM. *p<0.05 in paired comparison to J1. ELISA for secreted Vegf protein in 
ES cells relative to J1. *p<0.01 in paired comparison to J1.
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Homozygous Type 2B Vhl teratomas display growth advantage, enhanced hemangioma 
formation, and transcriptional dysregulation of HIF target genes. A. Growth curve for ES 
cell-derived teratomas (n=6 per genotype). Error bars indicate SEM. B. Gross appearance of 
representative Vhl2B/2B (left) and Vhl2B/+ teratomas. C.-F. Histological analysis of 
representative J1 (C.), Vhl-/- (D.), Vhl2B/+ (E.), and Vhl2B/2B (F.) teratoma morphology by 
H&E at 20X magnification. Note enhanced hemangioma (*) formation and hemorrhage in 
Vhl2B/2B relative to Vhl-/- teratoma. Scale bars indicate 100μm. G. Quantitative RT-PCR for 
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transcriptional activation of HIF targets Vegf, Glut1, EglN3, and Pfk1 in representative set of 
teratomas relative to J1. Cycle thresholds were corrected with 18S ribosomal RNA. Error 
bars indicate standard deviation. *p<0.05. **p<0.001.
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Exploration of hyper-angiogenic phenotype of homozygous Type 2B Vhl teratomas. 
Quantitative RT-PCR for transcriptional activation of angiogenesis-related genes Cdh5, Eng, 
Kdr, Nrp1, and Vegfc in a representative set of teratomas relative to J1. Cycle thresholds 
were corrected with 18S ribosomal RNA. Error bars indicate standard deviation. *p<0.05. 
**p<0.001.
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Homozygous Type 2B Vhl placentas display subtle vascular defects consistent with a Vhl-
null phenotype, and corresponding embryos display HIF target dysregulation despite normal 
morphology. A.-F. Histological analysis of Vhl2B/+ (A.-C.) and Vhl2B/2B (D.-F.) murine 
placentas, with H&E stain for morphology (A., C.) and immunohistochemistry for pVhl (B., 
E.) and for the HIF target Vegfa (C., F.) at 10X magnification. Arcs demarcate the maternal 
decidua (above) and placental (below) tissues. Note the lack of nucleated fetal RBCs (*) in 
the chorionic villi in Vhl2B/2B (D.) versus Vhl2B/+ (A.) placentas. Scale bars indicate 100μm. 
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G. Quantitative RT-PCR for transcriptional activation of HIF targets Vegf, Glut1, EglN3, 
and Pfk1 in E9.5 Vhl2B/2B embryos relative to representative Vhl2B/+ littermate. Cycle 
thresholds were corrected with 18S ribosomal RNA. Error bars indicate SEM. *p<0.05. 
**p<0.001.
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Adult Type 2B Vhl heterozygous mice develop mild vascular lesions and rare renal cortical 
microcysts, while transplacental ENU mutagenesis reveals renal tumor predisposition. A. - 
D. Histological analysis of representative adult Type Vhl2B/+ mouse tissues, including 
kidney (A.), adrenal gland (B.), and liver (C.) by H&E stain at 20X magnification. Vhl2B/+ 
mice frequently developed renal (not shown) and adrenal (B., *) angiectasis and 
occasionally developed simple renal cortical microcysts (A., Cy). E. - F. Histological 
analysis of ENU-mutagenized Vhl2B/+ mice by H&E stain at 20X magnification. While ENU 
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mutagenesis promoted benign simple and papillary microcysts formation in both Vhl2B/+ 
(not shown) and wild-type littermates (D.), borderline adenoma/adenocarcinoma (E.) and 
adenocarcinoma (F.) were selectively observed in mutagenized Vhl2B/+ mice at twelve 
months. Scale bars indicate 100μm.
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Table 1
Vhl genotype analysis of inter-heterozygous matings at birth and embryonic time points
Vhl E9.5 E10.5 Birth
+/+ 14 (32%) 13 (45%) 60 (36%)
2B/+ 20 (49%) 15 (52%) 107 (64%)
2B/2B 8 (19%) 1 (3%) 0 (0%)
Total 42 29 167
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Table 2
Summary of renal lesions observed in ENU-mutagenized Vhl2B/+ and wild-type littermates
4 months 12 months
Vhl +/+ (n=4) Vhl 2B/+ (n=8) Vhl +/+ (n=14) Vhl 2B/+ (n=10)
Renal Microcyst(s) 3 6 11 7
 -Papillary 3 1 2 1
Pre-neoplasia 0 1 0 0
Neoplasia 0 0 0 2
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